Semaglutide for the Treatment of Cannabis Use Disorder

NCT07879612 on ClinicalTrials.gov · last registry update 2026-10-19

A small phase 2 — 40 participants, against a typical 110. Due to report 30 January 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: Cannabis cue-reactivity. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Massachusetts General Hospital
Sponsor type: Other
Enrollment: 40
Started: 2027-01-10
Primary completion: 2029-01-30 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-10-19	First seen in registry	Registered as NOT_YET_RECRUITING, P2

Primary outcome

Cannabis cue-reactivity

Conditions studied

Cannabis Use Disorder · Cue-reactivity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.